Literature DB >> 11342657

Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate.

S R Thomas1, H Salahifar, R Mashima, N H Hunt, D R Richardson, R Stocker.   

Abstract

Induction of the heme-containing indoleamine 2,3-dioxygenase (IDO) by IFN-gamma is implicated in anti-microbial and pro-inflammatory activities of human macrophages. Antioxidants can modulate the expression of immune and inflammatory genes, and pyrrolidine dithiocarbamate (PDTC) is a frequently used antioxidant to inhibit the transcription factor NF-kappaB. Here we show that IFN-gamma treatment of human monocyte-derived macrophages (hMDMs) increased the proportion of oxidized glutathione. PDTC attenuated this increase and inhibited IDO activity, although it increased IDO protein expression and did not affect IDO mRNA expression and enzyme activity directly. Other antioxidants, 2-ME, ebselen, and t-butyl hydroquinone, inhibited IDO protein expression. Similar to PDTC, the heme biosynthesis inhibitor succinylacetone (SA) and the iron-chelator pyridoxal isonicotinoyl hydrazone inhibited cellular IDO activity without affecting protein expression, whereas addition of hemin or the heme precursor delta-aminolevulinic acid increased IDO activity. Also, incubation of IFN-gamma-activated hMDM with delta-[(14)C]-aminolevulinic acid resulted in the incorporation of label into immunoprecipitated IDO, a process inhibited by PDTC and SA. Furthermore, supplementation of lysates from PDTC- or SA-treated hMDM with hemin fully restored IDO activity to control levels, and hemin also reversed the inhibitory action of SA but not PDTC in intact cells. Together these results establish a requirement for de novo heme synthesis for IDO activity in IFN-gamma-activated hMDM. They show that, similar to other pro-inflammatory proteins, the activity of IDO is modulated by antioxidants though in the case of PDTC this takes place posttranslationally, in part by limiting the availability of heme for the formation of holo-IDO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342657     DOI: 10.4049/jimmunol.166.10.6332

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Authors:  Ursula Hainz; Petra Obexer; Christiana Winkler; Peter Sedlmayr; Osamu Takikawa; Hildegard Greinix; Anita Lawitschka; Ulrike Pötschger; Dietmar Fuchs; Stephan Ladisch; Andreas Heitger
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

2.  Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria.

Authors:  M H Azor; J C dos Santos; E A Futata; C A de Brito; C W Maruta; E A Rivitti; A J da Silva Duarte; M N Sato
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

3.  Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia.

Authors:  Chun-Yan Wang; Yan Shi; Ya-Nan Min; Xiao-Juan Zhu; Cheng-Shan Guo; Jun Peng; Xiao-Yuan Dong; Ping Qin; Jian-Zhi Sun; Ming Hou
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

4.  Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.

Authors:  Giada Mondanelli; Alice Coletti; Francesco Antonio Greco; Maria Teresa Pallotta; Ciriana Orabona; Alberta Iacono; Maria Laura Belladonna; Elisa Albini; Eleonora Panfili; Francesca Fallarino; Marco Gargaro; Giorgia Manni; Davide Matino; Agostinho Carvalho; Cristina Cunha; Patricia Maciel; Massimiliano Di Filippo; Lorenzo Gaetani; Roberta Bianchi; Carmine Vacca; Ioana Maria Iamandii; Elisa Proietti; Francesca Boscia; Lucio Annunziato; Maikel Peppelenbosch; Paolo Puccetti; Paolo Calabresi; Antonio Macchiarulo; Laura Santambrogio; Claudia Volpi; Ursula Grohmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-05       Impact factor: 11.205

Review 5.  Role of dendritic cell metabolic reprogramming in tumor immune evasion.

Authors:  Michael P Plebanek; Michael Sturdivant; Nicholas C DeVito; Brent A Hanks
Journal:  Int Immunol       Date:  2020-06-26       Impact factor: 4.823

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

7.  The cystine/glutamate antiporter regulates indoleamine 2,3-dioxygenase protein levels and enzymatic activity in human dendritic cells.

Authors:  Mildred L Mattox; June A D'Angelo; Zachary M Grimes; Edda Fiebiger; Bonny L Dickinson
Journal:  Am J Clin Exp Immunol       Date:  2012-11-30

8.  Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions: implications for the inhibition of dioxygenase activity by hydrogen peroxide.

Authors:  Mohammed Freewan; Martin D Rees; Tito S Sempértegui Plaza; Elias Glaros; Yean J Lim; Xiao Suo Wang; Amanda W S Yeung; Paul K Witting; Andrew C Terentis; Shane R Thomas
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

9.  Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein.

Authors:  Thangavel Samikkannu; Zainulabedin M Saiyed; K V K Rao; Dakshayani Kadiyala Babu; Jose W Rodriguez; Marina N Papuashvili; Madhavan P N Nair
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

10.  Fibroblasts from patients with Diamond-Blackfan anaemia show abnormal expression of genes involved in protein synthesis, amino acid metabolism and cancer.

Authors:  Federica Avondo; Paola Roncaglia; Nicoletta Crescenzio; Helena Krmac; Emanuela Garelli; Marta Armiraglio; Carlotta Castagnoli; Maria Francesca Campagnoli; Ugo Ramenghi; Stefano Gustincich; Claudio Santoro; Irma Dianzani
Journal:  BMC Genomics       Date:  2009-09-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.